Ocugen (OCGN) Set to Announce Earnings on Wednesday

Ocugen (NASDAQ:OCGN) is projected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Ocugen to post earnings of ($0.06) per share and revenue of $1.32 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Ocugen (NASDAQ:OCGN) last issued its earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $1.49 million during the quarter, compared to analyst estimates of $0.89 million. On average, analysts expect Ocugen to post ($0.25) EPS for the current fiscal year and ($0.25) EPS for the next fiscal year.

Ocugen Price Performance

Shares of OCGN opened at $0.72 on Tuesday. Ocugen has a 52-week low of $0.69 and a 52-week high of $2.73. The business’s 50 day moving average price is $1.02 and its two-hundred day moving average price is $1.42. The company has a debt-to-equity ratio of 4.17, a current ratio of 0.80 and a quick ratio of 0.80.

Insider Buying and Selling

In related news, CEO Shankar Musunuri sold 57,264 shares of the company’s stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $0.95, for a total transaction of $54,400.80. Following the transaction, the chief executive officer directly owned 1,030,771 shares of the company’s stock, valued at approximately $979,232.45. This represents a 5.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,051,982 shares of company stock valued at $1,088,801. Insiders own 3.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Weiss Ratings raised shares of Ocugen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Ocugen has an average rating of “Moderate Buy” and a consensus target price of $9.50.

About Ocugen

Ocugen, Inc (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and vaccines for infectious diseases. The company’s programs are designed to address serious conditions with limited treatment options, including inherited retinal diseases and diseases affecting the central retina.

Ocugen’s pipeline includes modifier gene therapy candidates intended to treat multiple retinal disorders with a single therapeutic approach. Its lead programs include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy associated with dry age-related macular degeneration, and OCU410ST for Stargardt disease.